Cargando…
Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization
Broadly HIV-1 neutralizing VRC01 class antibodies target the CD4-binding site of Env. They are derived from VH1–2*02 antibody heavy chains paired with rare light chains expressing 5-amino acid-long CDRL3s. They have been isolated from infected subjects but have not yet been elicited by immunization....
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6936959/ https://www.ncbi.nlm.nih.gov/pubmed/31801073 http://dx.doi.org/10.1016/j.celrep.2019.10.071 |
_version_ | 1783483793297899520 |
---|---|
author | Parks, K. Rachael MacCamy, Anna J. Trichka, Josephine Gray, Matthew Weidle, Connor Borst, Andrew J. Khechaduri, Arineh Takushi, Brittany Agrawal, Parul Guenaga, Javier Wyatt, Richard T. Coler, Rhea Seaman, Michael LaBranche, Celia Montefiori, David C. Veesler, David Pancera, Marie McGuire, Andrew Stamatatos, Leonidas |
author_facet | Parks, K. Rachael MacCamy, Anna J. Trichka, Josephine Gray, Matthew Weidle, Connor Borst, Andrew J. Khechaduri, Arineh Takushi, Brittany Agrawal, Parul Guenaga, Javier Wyatt, Richard T. Coler, Rhea Seaman, Michael LaBranche, Celia Montefiori, David C. Veesler, David Pancera, Marie McGuire, Andrew Stamatatos, Leonidas |
author_sort | Parks, K. Rachael |
collection | PubMed |
description | Broadly HIV-1 neutralizing VRC01 class antibodies target the CD4-binding site of Env. They are derived from VH1–2*02 antibody heavy chains paired with rare light chains expressing 5-amino acid-long CDRL3s. They have been isolated from infected subjects but have not yet been elicited by immunization. Env-derived immunogens capable of binding the germline forms of VRC01 B cell receptors on naive B cells have been designed and evaluated in knockin mice. However, the elicited antibodies cannot bypass glycans present on the conserved position N276 of Env, which restricts access to the CD4-binding site. Efforts to guide the appropriate maturation of these antibodies by sequential immunization have not yet been successful. Here, we report on a two-step immunization scheme that leads to the maturation of VRC01-like antibodies capable of accommodating the N276 glycan and displaying autologous tier 2 neutralizing activities. Our results are relevant to clinical trials aiming to elicit VRC01 antibodies. |
format | Online Article Text |
id | pubmed-6936959 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
record_format | MEDLINE/PubMed |
spelling | pubmed-69369592019-12-30 Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization Parks, K. Rachael MacCamy, Anna J. Trichka, Josephine Gray, Matthew Weidle, Connor Borst, Andrew J. Khechaduri, Arineh Takushi, Brittany Agrawal, Parul Guenaga, Javier Wyatt, Richard T. Coler, Rhea Seaman, Michael LaBranche, Celia Montefiori, David C. Veesler, David Pancera, Marie McGuire, Andrew Stamatatos, Leonidas Cell Rep Article Broadly HIV-1 neutralizing VRC01 class antibodies target the CD4-binding site of Env. They are derived from VH1–2*02 antibody heavy chains paired with rare light chains expressing 5-amino acid-long CDRL3s. They have been isolated from infected subjects but have not yet been elicited by immunization. Env-derived immunogens capable of binding the germline forms of VRC01 B cell receptors on naive B cells have been designed and evaluated in knockin mice. However, the elicited antibodies cannot bypass glycans present on the conserved position N276 of Env, which restricts access to the CD4-binding site. Efforts to guide the appropriate maturation of these antibodies by sequential immunization have not yet been successful. Here, we report on a two-step immunization scheme that leads to the maturation of VRC01-like antibodies capable of accommodating the N276 glycan and displaying autologous tier 2 neutralizing activities. Our results are relevant to clinical trials aiming to elicit VRC01 antibodies. 2019-12-03 /pmc/articles/PMC6936959/ /pubmed/31801073 http://dx.doi.org/10.1016/j.celrep.2019.10.071 Text en This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Parks, K. Rachael MacCamy, Anna J. Trichka, Josephine Gray, Matthew Weidle, Connor Borst, Andrew J. Khechaduri, Arineh Takushi, Brittany Agrawal, Parul Guenaga, Javier Wyatt, Richard T. Coler, Rhea Seaman, Michael LaBranche, Celia Montefiori, David C. Veesler, David Pancera, Marie McGuire, Andrew Stamatatos, Leonidas Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization |
title | Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization |
title_full | Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization |
title_fullStr | Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization |
title_full_unstemmed | Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization |
title_short | Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization |
title_sort | overcoming steric restrictions of vrc01 hiv-1 neutralizing antibodies through immunization |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6936959/ https://www.ncbi.nlm.nih.gov/pubmed/31801073 http://dx.doi.org/10.1016/j.celrep.2019.10.071 |
work_keys_str_mv | AT parkskrachael overcomingstericrestrictionsofvrc01hiv1neutralizingantibodiesthroughimmunization AT maccamyannaj overcomingstericrestrictionsofvrc01hiv1neutralizingantibodiesthroughimmunization AT trichkajosephine overcomingstericrestrictionsofvrc01hiv1neutralizingantibodiesthroughimmunization AT graymatthew overcomingstericrestrictionsofvrc01hiv1neutralizingantibodiesthroughimmunization AT weidleconnor overcomingstericrestrictionsofvrc01hiv1neutralizingantibodiesthroughimmunization AT borstandrewj overcomingstericrestrictionsofvrc01hiv1neutralizingantibodiesthroughimmunization AT khechaduriarineh overcomingstericrestrictionsofvrc01hiv1neutralizingantibodiesthroughimmunization AT takushibrittany overcomingstericrestrictionsofvrc01hiv1neutralizingantibodiesthroughimmunization AT agrawalparul overcomingstericrestrictionsofvrc01hiv1neutralizingantibodiesthroughimmunization AT guenagajavier overcomingstericrestrictionsofvrc01hiv1neutralizingantibodiesthroughimmunization AT wyattrichardt overcomingstericrestrictionsofvrc01hiv1neutralizingantibodiesthroughimmunization AT colerrhea overcomingstericrestrictionsofvrc01hiv1neutralizingantibodiesthroughimmunization AT seamanmichael overcomingstericrestrictionsofvrc01hiv1neutralizingantibodiesthroughimmunization AT labranchecelia overcomingstericrestrictionsofvrc01hiv1neutralizingantibodiesthroughimmunization AT montefioridavidc overcomingstericrestrictionsofvrc01hiv1neutralizingantibodiesthroughimmunization AT veeslerdavid overcomingstericrestrictionsofvrc01hiv1neutralizingantibodiesthroughimmunization AT panceramarie overcomingstericrestrictionsofvrc01hiv1neutralizingantibodiesthroughimmunization AT mcguireandrew overcomingstericrestrictionsofvrc01hiv1neutralizingantibodiesthroughimmunization AT stamatatosleonidas overcomingstericrestrictionsofvrc01hiv1neutralizingantibodiesthroughimmunization |